In a systematic review and meta-analysis involving CSF biomarkers of glial activation, there was only a mild elevation of MCP-1 that did not differentiate between Alzheimer’s disease patients and controls with normal cognitive function [27]. The gene discussed is CCL2; the disease is Alzheimer disease.